Bluejay Diagnostics (BJDX) vs Competitors Direct Analysis
Bluejay Diagnostics (NASDAQ:BJDX – Get Rating) is one of 216 public companies in the “surgical and medical devices” industry, but how does it stand out from its peers? We will compare Bluejay Diagnostics to related companies based on its risk strength, analyst recommendations, earnings, profitability, valuation, dividends and institutional ownership.
Valuation and benefits
This table compares the revenue, earnings per share (EPS), and valuation of Bluejay Diagnostics and its peers.
|Gross revenue||Net revenue||Price/earnings ratio|
|Diagnosis Bluejay||N / A||-$3.49 million||-2.95|
|Bluejay Diagnostics Competitors||$1.14 billion||$83.89 million||-512.35|
Bluejay Diagnostics peers have higher revenue and profit than Bluejay Diagnostics. Bluejay Diagnostics trades at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a summary of recent reviews from Bluejay Diagnostics and its peers, as reported by MarketBeat.
|Sales Ratings||Hold odds||Buy reviews||Strong buy odds||Rating|
|Bluejay Diagnostics Competitors||626||3051||7232||163||2.63|
Bluejay Diagnostics currently has a consensus price target of $10.00, suggesting a potential upside of 747.46%. As a group, the Surgical and Medical Instruments companies have an upside potential of 31.94%. Given Bluejay Diagnostics’ higher consensus rating and higher likely upside, equity research analysts clearly believe Bluejay Diagnostics is more favorable than its peers.
Institutional and Insider Ownership
45.4% of shares in Bluejay Diagnostics are held by institutional investors. In comparison, 50.9% of the shares of all “Surgical and medical instruments” companies are held by institutional investors. 45.3% of shares in Bluejay Diagnostics are held by insiders of the company. By comparison, 14.7% of the shares of all “Surgical and Medical Devices” companies are held by insiders of the company. Strong institutional ownership indicates that endowments, large fund managers, and hedge funds believe a stock will outperform the market over the long term.
This table compares the net margins, return on equity, and return on assets of Bluejay Diagnostics and its peers.
|Net margins||Return on equity||return on assets|
|Diagnosis Bluejay||N / A||-52.42%||-44.29%|
|Bluejay Diagnostics Competitors||-738.88%||-55.34%||-19.44%|
Bluejay Diagnostics beats its peers on 7 of the 12 factors compared.
Bluejay Diagnostics Company Profile
(Get a rating)
Bluejay Diagnostics, Inc., a diagnostics company, develops and markets patient-directed products for the triage, diagnosis and monitoring of disease progression in the United States. It develops the Symphony Platform, a technology platform including the Symphony Fluorescence immunoanalyzer that orchestrates blood processing, biomarker isolation and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers the ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. Furthermore, he is developing biomarkers for the detection of other diseases such as hsTNT/I for myocardial damage and NT-proBNP for heart failure. It has a license and supply agreement with Toray Industries, Inc. for the manufacture and distribution of protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Get news and reviews for Bluejay Diagnostics Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Bluejay Diagnostics and related companies with MarketBeat.com’s FREE daily newsletter.